Merck Fosamax Study Shows Benefit Vs. Actonel; Aventis/P&G Fault Endpoint

A Merck head-to-head trial showing an efficacy advantage for its osteoporosis agent Fosamax versus Actonel is "misleading" because the claim is based on bone mineral density rather than the preferred fracture risk endpoint, competitors maintain